Lydie Trautmann has not added Biography.
If you are Lydie Trautmann and would like to personalize this page please email our Author Liaison for assistance.
+1 Frameshifting as a novel mechanism to generate a cryptic cytotoxic T lymphocyte epitope derived from human interleukin 10.
The Journal of experimental medicine Feb, 2002 | Pubmed ID: 11828010
Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens.
European journal of immunology Nov, 2002 | Pubmed ID: 12555663
Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.
Blood Feb, 2004 | Pubmed ID: 14563644
Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses.
Journal of immunology (Baltimore, Md. : 1950) Nov, 2005 | Pubmed ID: 16237109
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.
Nature medicine Oct, 2006 | Pubmed ID: 16917489
The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells.
Journal of immunology (Baltimore, Md. : 1950) Jan, 2007 | Pubmed ID: 17202340
[Inhibition of the PD-1 pathway restores the effector function of HIV-specific T cells].
Médecine sciences : M/S Jan, 2007 | Pubmed ID: 17212925
Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection.
Nature medicine Mar, 2008 | Pubmed ID: 18311149
T-cell exhaustion in HIV infection.
Current HIV/AIDS reports Feb, 2008 | Pubmed ID: 18417030
Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells.
Journal of virology Oct, 2008 | Pubmed ID: 18667516
Drug resistance mutations and the cellular immune response: a valuable synergy for the development of novel immune therapies.
Current opinion in HIV and AIDS Mar, 2007 | Pubmed ID: 19372876
Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections.
Current opinion in HIV and AIDS May, 2007 | Pubmed ID: 19372890
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.
Nature medicine Aug, 2009 | Pubmed ID: 19543283
Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.
Nature medicine Apr, 2010 | Pubmed ID: 20208540
New approaches to design HIV-1 T-cell vaccines.
Current opinion in HIV and AIDS Sep, 2010 | Pubmed ID: 20978376
Solving vaccine mysteries: a systems biology perspective.
Nature immunology Aug, 2011 | Pubmed ID: 21772284
Ex vivo measurement of the cytotoxic capacity of human primary antigen-specific CD8 T cells.
Journal of immunological methods Jan, 2012 | Pubmed ID: 21996428
Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation.
Journal of immunology (Baltimore, Md. : 1950) Feb, 2012 | Pubmed ID: 22210916
Foxo3a: an integrator of immune dysfunction during HIV infection.
Cytokine & growth factor reviews Aug-Oct, 2012 | Pubmed ID: 22748238
Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection.
Blood Oct, 2012 | Pubmed ID: 22955926
Beyond surface markers with a universal cell secretion assay.
Cytometry. Part A : the journal of the International Society for Analytical Cytology Feb, 2013 | Pubmed ID: 22997009
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved